Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov;32(11):2307-2315.
doi: 10.1038/s41375-018-0285-8. Epub 2018 Oct 12.

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells

Marion Alcantara  1   2 , Melania Tesio  2 , Carl H June  3   4   5 , Roch Houot  6   7   8
Affiliations
Review

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells

Marion Alcantara et al. Leukemia. 2018 Nov.

Abstract

Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrated remarkable efficacy for the treatment of B-cell malignancies. The development of CAR T-cells against T-cell malignancies appears more challenging due to the similarities between the therapeutic, normal and malignant T-cells. The obstacles include CAR T-cell fratricide, T-cell aplasia, and contamination of CAR T-cell products with malignant T-cells. Here, we review these challenges and propose solutions to overcome these limitations.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest M.A. received consulting fees/honoraria from Novartis. C.H.J. reports sponsored research from Novartis, patents licensed to Novartis by the University of Pennsylvania and he is a shareholder in Tmunity. R.H. received consulting fees/honoraria from Novartis and Kite/Gilead. The remaining author declares no conflict of interest.

Figures

Fig. 1
Fig. 1
Challenges and solutions in targeting T-cell antigens with CAR T-cells
See this image and copyright information in PMC

References

    1. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–98. - PMC - PubMed
    1. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5. - PubMed
    1. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15:31–46. - PubMed
    1. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bitten-court H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. - PMC - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. - PMC - PubMed

LinkOut - more resources